Study Assessing Pain Relief After Replacement of the Knee (SPARK)
A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, and Efficacy Trial of ATX-101 in Subjects Undergoing Total Knee Arthroplasty
Sponsor: Allay Therapeutics, Inc.
Terminated
Based on positive data from the dose-ranging portion of the study, Sponsor decided as of May 28, 2024 not to move forward with the previously designed global ATX101-TKA-003 study.
This PHASE2 trial investigates Acute Postoperative Pain and is currently terminated or withdrawn. Allay Therapeutics, Inc. leads this study, which shows 15 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 10 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allay Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .